Skip Navigation


JAC Advance Access originally published online on January 28, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/3/599    most recent
dkg112v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ackermann, G.
Right arrow Articles by Rodloff, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ackermann, G.
Right arrow Articles by Rodloff, A. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 599-603
© 2003 The British Society for Antimicrobial Chemotherapy

Prevalence and association of macrolide–lincosamide– streptogramin B (MLSB) resistance with resistance to moxifloxacin in Clostridium difficile

Grit Ackermann1,*, Angelika Degner1, Stuart H. Cohen2, Joseph Silva Jr2 and Arne C. Rodloff1

1 Institute for Medical Microbiology and Epidemiology of Infectious Diseases, University of Leipzig, Liebigstrasse 24, 04103 Leipzig, Germany; 2 Department of Internal Medicine, Division of Infectious Diseases and Immunologic Diseases, University of California–Davis, Medical Centre, Sacramento, CA, USA

Received 9 August 2002; returned 10 October 2002; revised 25 November 2002; accepted 4 December 2002

Clostridium difficile remains the leading cause of nosocomially acquired diarrhoea. C. difficile usually exhibits resistance against ß-lactam antibiotics, whereas susceptibility to other drugs may vary. This study investigated the antimicrobial susceptibility of C. difficile to different antibiotics over a period of time and characterizes molecular mechanisms for resistance. One hundred and seventy-three toxigenic and 19 non-toxigenic C. difficile strains, recovered from patients in two university hospitals in Germany between 1986 and 2001, were investigated for their susceptibility to erythromycin, clindamycin, moxifloxacin, vancomycin and metronidazole employing the Etest. The genetic background for resistance was analysed using PCR and DNA sequencing. All strains were susceptible to vancomycin and metronidazole. Resistance to erythromycin, clindamycin and moxifloxacin was found in 27%, 36% and 12% of the tested strains, respectively. High-level resistance (MIC > 128 mg/L) against erythromycin and clindamycin was detected in 25% of the strains tested. Thirty-four of the macrolide–lincosamide–streptogramin B (MLSB)-resistant strains carried the erythromycin resistance methylase gene. The results indicate an increase in the prevalence of resistance to MLSB and fluoroquinolone antibiotics in C. difficile. Fluoroquinolone resistance is associated with resistance to MLSB antimicrobials.

Keywords: Clostridium difficile, antimicrobials, susceptibility

* Corresponding author. Tel: +49-341-971-5200; Fax: +49-341-971-5209; E-mail: ackermg{at}medizin.uni-leipzig.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Med MicrobiolHome page
E. Mutlu, A. J. Wroe, K. Sanchez-Hurtado, J. S. Brazier, and I. R. Poxton
Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland
J. Med. Microbiol., July 1, 2007; 56(7): 921 - 929.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. Drudy, T. Quinn, R. O'Mahony, L. Kyne, P. O'Gaora, and S. Fanning
High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile
J. Antimicrob. Chemother., December 1, 2006; 58(6): 1264 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
H. Pituch, J. S. Brazier, P. Obuch-Woszczatynski, D. Wultanska, F. Meisel-Mikolajczyk, and M. Luczak
Prevalence and association of PCR ribotypes of Clostridium difficile isolated from symptomatic patients from Warsaw with macrolide-lincosamide-streptogramin B (MLSB) type resistance
J. Med. Microbiol., February 1, 2006; 55(2): 207 - 213.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
P. Spigaglia and P. Mastrantonio
Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods
J. Med. Microbiol., November 1, 2004; 53(11): 1129 - 1136.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Schaumann, R. Blatz, J. Beer, G. Ackermann, and A. C. Rodloff
Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli
J. Antimicrob. Chemother., February 1, 2004; 53(2): 318 - 324.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. Ackermann, D. Adler, and A. C. Rodloff
In vitro activity of linezolid against Clostridium difficile
J. Antimicrob. Chemother., March 1, 2003; 51(3): 743 - 745.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.